Atrinsic (NASDAQ:PTIX) Trading Down 0.6% – Here’s What Happened

Atrinsic Inc. (NASDAQ:PTIX) shares traded down 0.6% during trading on Monday . The stock traded as low as $0.3412 and last traded at $0.3977. 2,989 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 115,453 shares. The stock had previously closed at $0.40.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Atrinsic in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Atrinsic Price Performance

The business’s fifty day moving average price is $0.96 and its 200-day moving average price is $2.29. The stock has a market capitalization of $766,765.60, a price-to-earnings ratio of -0.05 and a beta of 1.10.

Atrinsic (NASDAQ:PTIX) last posted its earnings results on Wednesday, November 26th. The company reported ($0.47) earnings per share for the quarter.

About Atrinsic

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.